Abstract
Systemic chemotherapy is an important treatment modality for metastatic hepatocellular carcinoma (HCC); however, the predictive factors of outcome and tumor response have not been fully investigated. The aim of this study was to identify factors that could be used to predict outcome and tumor response to systemic chemotherapy in patients with metastatic HCC. We retrospectively examined 82 consecutive patients with metastatic HCC undergoing systemic chemotherapy to investigate factors associated with outcome and tumor response. The patients underwent 5-fluorouracil, mitoxantrone and cisplatin (FMP) therapy. The overall objective response rate was 22% (95% confidence interval, 14-32), and the median survival time and 1-year survival for all patients were 11.2 months and 43.5%, respectively. Multivariate analysis demonstrated that the absence of radiologically active intrahepatic disease (P = 0.02) and ascites (P = 0.002) was independent favorable prognostic factors. Although multivariate analysis revealed no significant predictive factors of tumor response, the response rates in patients without radiologically active intrahepatic disease (response rate, 46%) tended to be higher than those in patients with active intrahepatic dise...Continue Reading
References
Jul 1, 1992·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·S OkadaK Aoki
Aug 15, 1985·Cancer·K OkudaK Ohnishi
Feb 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D L Dexter, J T Leith
Aug 1, 1973·The British Journal of Surgery·R N PughR Williams
Nov 1, 1993·Cancer·Y Z PattB Levin
Jun 1, 1996·Cancer·K E StuartR L Jenkins
Dec 9, 1997·Japanese Journal of Clinical Oncology·H NagahamaM Yoshimori
Dec 24, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J M LlovetJ Bruix
Oct 31, 2001·Seminars in Oncology·A Aguayo, Y Z Patt
Mar 22, 2002·Cancer·Thomas W T LeungPhilip J Johnson
May 29, 2004·Journal of Gastroenterology·Tsai-Shen YangWen-Cheng Chang
Jun 16, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Anna K NowakMichael Findlay
Jan 8, 2005·Cancer·Masafumi IkedaChigusa Morizane
Apr 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Melanie B Thomas, Andrew X Zhu
Oct 20, 2005·Journal of the National Cancer Institute·Winnie YeoPhilip J Johnson
Nov 4, 2005·Journal of Neurosurgery·Jun DeguchiToshihiko Kuroiwa
Jul 25, 2006·Critical Reviews in Oncology/hematology·Alejandro FornerJordi Bruix
Aug 16, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ghassan K Abou-AlfaLeonard B Saltz
Nov 28, 2007·Cancer·Andrew X Zhu
May 9, 2008·Blood·Massimo Franchini, Giuseppe Lippi
Citations
May 13, 2014·PloS One·Fan WangChuanyong Guo
Jan 15, 2013·Digestive Diseases and Sciences·Suna ZhouJiansheng Wang
Feb 9, 2012·Cancer Letters·Jianhua JiaoChangliang Zhu
Aug 26, 2015·Journal of Experimental & Clinical Cancer Research : CR·Silvia UssaiFrancesca Pentimalli
Mar 17, 2017·European Journal of Medicinal Chemistry·Lei ZhangJing Wang
Oct 5, 2017·Cancer Control : Journal of the Moffitt Cancer Center·Jennifer EatridesRichard Kim
Feb 1, 2008·Annals of Surgical Oncology·Melanie B ThomasPhilip Johnson
Oct 31, 2009·World Journal of Hepatology·Toru Ishikawa
Apr 26, 2012·Applied Immunohistochemistry & Molecular Morphology : AIMM·Hua YangMing Lin
Feb 23, 2020·Cancers·Dianshuai HuangFei Sun
Mar 24, 2010·American Journal of Clinical Oncology·Ji-Won KimYung-Jue Bang
Dec 5, 2019·Liver Cancer·Li-Chun LuAnn-Lii Cheng